Pan D; Kumar A; Lipof JJ; Chung A; Wolf JL; Martin TG 3rd; Arora S; Sayre PH; Chari A · 2026 · Cancer
Paper
G-protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed/refractory multiple myeloma. Although the T-cell-engaging bispecific antibody talquetamab is currently the only approved anti-GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti-GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T-cell-engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B-cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T-cell engagers currently in development.
Analysis
Preparing paper insights from the available abstract and paper details.
Discovery
Wu T; Lv B; Wang H; He G; Fu Y; Ji X; Zeng Y; Ni D; Qiu J; Hua K
Xudong Wang; Jin Zhang
Goldman C
Hofmann M; Unverdorben F; Pszolla MG; Aschmoneit N; Hutt M; Manz T; Schuster H; Hukelmann J; Acs A; Tenkerian C; Missel S; Mølhøj M; Schräder C; Wagner C; Maurer D; Bunk S; Reinhardt C
Wang L; Gong S; Wang J; Bao Y; Mei N; Lu X; Chen W; Xi L; Zhang H; Chen X; Ning P; Fan X; Wang H
Pamenter G; Ovari G; Kulkarni A; Williams-Fegredo T; Knevelman C; Mitrophanous K; Davies L; Foroutan F; Townsend M; Goldrick S; Bracewell DG
Source record